

REMARKS

Claims 15, 17-19, 24, 25, 27-32, 35-44 were allowed in pending in the subject application. In this Amendment, Applicants have amended claims 15, 28, 36 and 38-40.

Claims 15 and 38-40 have been amended to include the terms “(a)” and “(b)” before the first recitation of the terms “1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine” and “metformin,” respectively. As amended, these claims now recite a method of treatment comprising both (a) 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine and (b) metformin. Applicants believe these amendments to claims 15 and 38-40 more precisely recite the subject matter of these claims.

Claim 28 has been amended to replace the term “500-2850 mg” with the term “500 mg to 2850 mg.”

Claim 36 has been amended to replace the term “an” which precedes the term “pharmaceutically” in the last line of the claim with the term “a.”

Claims 38-40 have been further amended to include the term “in” before the phrase “the form of a fixed combination.”

Support for the above amendments can be found throughout the original specification and in the original claims.

Each of the above amendments merely embodies the correction of formal matters without changing the scope of the allowed claims. Pursuant to MPEP § 714.16(a), Applicants believe the amendments are (A) needed for proper disclosure or protection of the invention, and (B) require no substantial amount of additional work on the part of the office.

No new matter is added by this amendment, and Applicants respectfully request its entry.

U.S. Application No.: 14/161,007
Response after Notice of Allowance dated July 27, 2015
Attorney Docket No.: 01-2051-US-3

CONCLUSION

Applicants respectfully request prompt consideration of the amended claims and entry of this amendment. No additional fee is believed due. However, if any additional fee is due, the Examiner is authorized to charge the fee to Applicants' Deposit Account No. 02-2955.

If a telephonic or personal interview is deemed necessary in connection with this application, the Examiner is kindly requested to contact the undersigned at the telephone number listed below.

Respectfully submitted,

/David L. Kershner/
David L. Kershner
Attorney for Applicant(s)
Reg. No. 53,112

Patent Department
Boehringer Ingelheim Corp.
900 Ridgebury Road
P.O. Box 368
Ridgefield, CT 06877
Tel.: (203) 448-1844
Fax: (203) 837-5616

Date: July 29, 2015